메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류
인문학
인문학 일반 역사학 철학 종교학 어문학 기타 인문학
사회과학
사회과학 일반 경영학 관광학 교육학 군사학 문헌정보학 법학 사회학 신문방송학 심리과학 정치외교학 지리학 행정학 경제학 무역학 인류학 기타 사회과학
자연과학
자연과학 일반 물리학 생물학 생활과학 수학·통계학 천문학 지구과학 화학 기타 자연과학
공학
공학 일반 건축공학 기계공학 산업공학 재료·에너지공학 전기전자공학 조선해양공학 화학공학 컴퓨터학 기타공학
의약학
의학 일반 간호학 수의학 약학 한의학 기초의학 임상의학 기타 의약학
농수해양학
농수해양학 일반 농학 수산학 식품과학 임학 축산학 해상운송학 기타 농수해양학
예술체육학
예술 일반 디자인 미술 미용 사진 음악학 의상 체육 공연매체예술 기타 예술체육학
복합학
학제간연구 과학기술학 뇌인지과학 기술정책 기타 복합학

ENG

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Seoung Hoon Lee (Department of Oral Microbiology and Immunology Wonkwang University)
저널정보
대한골다공증학회 Osteoporosis and Sarcopenia Osteoporosis and Sarcopenia Vol.4 No.4
발행연도
2018.1
수록면
150 - 150 (1page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Recently, Hong et al. [1] reported the application of human umbilical cord blood derived mesenchymal stem cells (hUCB-MSCs) on bone regeneration in ovariectomized rats with femoral defects. In this study, the bone regeneration was comparable to nonosteoporotic bone regeneration and it was concluded that hUCB-MSCs could be used in alternative stem cell therapy. MSCs, which possess characteristics like self-renewal and differentiation potential, have been isolated from a variety of tissue sources including bone marrow, peripheral blood, umbilical cord blood, adipose tissue, fetal liver and lung, dental pulp, skeletal muscle, and synovium [2]. Particularly, the hUCB-MSCs have been proposed as a potential source of MSCs for cell therapy for bone diseases like osteoporosis, instead of bone marrow-derived MSCs (BM-MSCs) or adipose tissue-derived MSCs, owing to its multiple advantages including easy harvesting, immunosuppressive potential, and a stronger capacity to differentiate into osteoblasts than other MSC sources [3]. For the past several years, MSCs including hUCB-MSCs have been applied in animal models or human clinical trials for various disease treatments such as osteoarthritis, graft-versus-host disease (GVHD), multiple sclerosis, spinal cord injury, and liver diseases [2]. In fact, a number of phase I/II trials were processed to identify safety issues and viability of clinical MSC therapy in humans. Recent several studies reported that the clinical application of both autologous and allogenic MSCs did not show severe adverse effects in several animal experiments. Therefore, MSC therapy is expected to find clinical application in human diseases [2]. However, there are some critical issues that need to be addressed before MSCs can be used for clinical therapy in humans, most important of which is the safety issue. Tumor support or the suppression effect of MSCs has been reported and the potential tumorigenicity of MSC-based therapy was recently presented [4]. Despite many clinical results and ongoing clinical trials, there is, as yet, no clear report regarding the long-term safety of MSCs including hUCB-MSCs in humans. In addition, putative profibrogenic potential of MSCs, as shown in liver fibrosis induced by human BM-MSCs [5], poses another obstacle in their therapeutic use. Furthermore, MSCs are mostly a heterogeneous mix of different cell populations that are defined by cell surface phenotypes and/or functional ability to differentiate into multiple cell lineages including osteoclast, chondrocyte, adipocyte, or skeletal myocyte lineages. Heterogeneity may exist within and between MSC populations from diverse sources including donors, tissue, clonal subpopulations and single cells, according to age, sex, genetics, environmental conditions, aging, and epigenetic modifications [6]. Recently, it was reported that the angiogenesis capacity of hUCB-MSC for peripheral artery disease therapy depended on the donor [7]. Although these serious constraints in the therapeutic use of MSCs need to be resolved, the use of MSCs in regenerative medicine remains promising due to their attractive advantages including anti-inflammatory and immunomodulatory features. MSCs may be able to treat a broad range of diseases from repair of skeletal diseases to treatment of GVHD. Thus, more rigorous clinical trials and animal studies are necessary to make MSC therapy a safe and effective therapeutic approach for multiple diseases.

목차

등록된 정보가 없습니다.

참고문헌 (7)

참고문헌 신청
홍부휘 / 2018 / Bone regeneration with umbilical cord blood mesenchymal stem cells in femoral defects of ovariectomized rats / Osteoporosis and Sarcopenia 4(3):95~101 dbpia Uder C / 2018 / Mammalian MSC from selected species: features and applications / Cytometry 93:32~49 google schola Wang M / 2009 / The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro / Immunology 126:220~232 google schola Barkholt L / 2013 / Risk of tumorigenicity in mesenchymal stromal cell-based therapies–bridging scientific observations and regulatory viewpoints / Cytotherapy 15:753~759 google schola Russo FP / 2006 / The bone marrow functionally contributes to liver fibrosis / Gastroenterology 130:1807~1821 google schola

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0